Aurinia Pharmaceuticals (NASDAQ:AUPH)

CAPS Rating: 3 out of 5

Caps

How do you think AUPH will perform against the market?

Add Stock to CAPS Watchlist

All Players

43 Outperform
5 Underperform
 

All-Star Players

13 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top AUPH Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

zzlangerhans (99.83)
Submitted October 06, 2016

Aurinia wins the comeback kid award after rebounding to 5.5 just six weeks after crashing to 1.73 on word of a substantial mortality imbalance favoring control in the AURA-LV phase IIb trial of voclosporin for lupus nephritis. Aurinia insists that… More

AUPH VS S&P 500 (SPY)

AUPH Summary

  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about AUPH.

Recs

0
Member Avatar gunterle (69.34) Submitted: 10/13/2017 10:34:54 AM : Outperform Start Price: $6.76 AUPH Score: -9.75

new strong buy today

Recs

0
Member Avatar InvestYoung (65.41) Submitted: 8/17/2017 1:07:23 PM : Outperform Start Price: $6.20 AUPH Score: -5.98

It is going back up. I can feel it. Buy it while it's low!

https://www.fool.com/investing/2017/08/17/3-reasons-to-buy-aurinia-pharmaceuticals-stock-rig.aspx

Recs

0
Member Avatar TMFEBCapital (42.88) Submitted: 7/12/2017 3:51:03 PM : Outperform Start Price: $6.26 AUPH Score: -7.15

There aren't any FDA approved therapies for lupus nephritis (LN), and the patient population in the U.S. alone is up to 200k people. Current treatments fall short with single digit complete remission rates, but this company's drug - voclosporin -- delivered almost 50% rates in phase 2. A phase 3 is underway, and if successful, could result in this becoming a 9-figure (plus) drug.

Leaderboard

Find the members with the highest scoring picks in AUPH.

Score Leader

jack0071

jack0071 (72.16) Score: +173.90

The Score Leader is the player with the highest score across all their picks in AUPH.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
jack0071 72.16 12/28/2016 Outperform 5Y $2.14 +187.38% +13.48% +173.90 0 Comment
hayrettin 70.58 1/24/2017 Outperform 5Y $3.00 +105.00% +12.91% +92.09 0 Comment
sublimeinvestor 30.17 11/30/2016 Outperform 5Y $3.04 +102.30% +16.66% +85.64 0 Comment
Plasmidologist 31.30 11/30/2016 Outperform 5Y $3.04 +102.30% +16.66% +85.64 0 Comment
shredlee 84.31 2/15/2017 Outperform 1Y $3.58 +71.79% +9.86% +61.93 0 Comment
eyezie1 < 20 11/21/2016 Outperform 5Y $3.58 +71.75% +17.11% +54.64 0 Comment
t0bes < 20 11/16/2016 Outperform 5Y $4.23 +45.39% +18.17% +27.22 0 Comment
clangmead 64.79 3/3/2017 Outperform 5Y $4.70 +30.85% +7.95% +22.90 1 Comment
chrispycrunch 90.03 7/17/2017 Underperform 5Y $7.49 -17.90% +4.56% +22.46 0 Comment
mmr23 < 20 3/7/2017 Underperform NS $6.82 -9.82% +8.37% +18.19 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for AUPH.

Featured Broker Partners